| Name | Title | Contact Details |
|---|
Premia Managing Agency Limited ("PMAL") provides risk-transfer and run-off solutions for other Lloyds syndicates and capital providers. It is responsible for managing the run-off of Syndicate 1884 for the Year of Account 2018, following cessation of live market underwriting on 31 December 2018. PMAL is a subsidiary of Premia Holdings Ltd, a Bermuda based legacy reinsurance group with operations in the USA, Bermuda, UK and EU. PMAL is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority.
ChromaScape is a specialty chemicals company based in Independence, Ohio, with a production facility in Stow. Founded in 1998, it has roots dating back to 1968. The company operates six manufacturing and distribution facilities across the U.S. and boasts over 100 years of combined expertise in colorant formulation and supply chain management. ChromaScape focuses on lean manufacturing, digital integration, and customer-centric processes to enhance quality and efficiency. ChromaScape offers a range of products, including colorants and additives for various industries. In landscaping, it provides Amerimulch® colored mulch and rubber/aggregate colorants. For packaging, it supplies Aquablak® aqueous carbon black dispersions and CEL Chemical adhesives for waterproof corrugated board. In construction, its Innotech® decorative concrete colorants and ChromaPave® asphalt sealcoat colorants are widely used. The company has expanded its portfolio through strategic acquisitions, enhancing its offerings in printing, packaging, and consumer specialties.
We are a global precision engineering company manufacturing, supplying and distributing cutting tools to leading industrial companies from our facilities around the world. With a legacy based on commitment to quality, we have been serving our customers from our headquarters in Cavan, Ireland for almost 60 years.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.